Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
作者信息
Wigle W W
出版信息
Can Med Assoc J. 1968 Feb 10;98(6):314-7.
Abstract
摘要
相似文献
1
Drug safety: the viewpoint of the pharmaceutical manufacturing industry.药物安全性：制药行业的观点
Can Med Assoc J. 1968 Feb 10;98(6):314-7.
2
3
[Suggestions and recommendations for standardization of the systemic "routine" control during the production of the pharmaceutical dosage forms and their manufacturing].
Boll Chim Farm. 1971 Mar;110(3):131-46 contd.
4
Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.人用和兽用药品：良好生产规范及某些非处方药产品的拟议豁免规定。
Fed Regist. 1978 Sep 29;43(190 Pt 2):45013-89.
5
Panel discussion: practical importance of generic equivalence.小组讨论：仿制药等效性的实际重要性。
Ann Clin Res. 1974;6(0):suppl 11:79-88.
6
Report on the PQRI impurity characterization and quantification best practices survey.关于PQRI杂质特征描述与定量最佳实践调查的报告。
Pharm Res. 2006 Feb;23(2):440-6. doi: 10.1007/s11095-005-9646-x.
7
8
GMPs vs GCPs: manufacturing and compounding definitions.药品生产质量管理规范（GMPs）与药物临床试验质量管理规范（GCPs）：生产与配制的定义
Int J Pharm Compd. 2013 Sep-Oct;17(5):356.
9
Drug product quality.药品质量
Exp Med Surg. 1971;29(1):135-44.
10
The concept of drug expiration dating.药品有效期的概念。
Bull Parenter Drug Assoc. 1969 Jan-Feb;23(1):48-52.
本文引用的文献
1
FDA censorship.
Clin Pharmacol Ther. 1967 May-Jun;8(3):359-61. doi: 10.1002/cpt196783359.
2
The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets.固体剂型的生物药剂学性质。I. 对23个品牌保泰松片的评价
Can Med Assoc J. 1967 Jun 10;96(23):1513-20.
Zotero 插件